KRAS and ovarian carcinoma: Defactinib, a small-molecule and well-tolerated FAK inhibitor, has been evaluated in phase I/Ib study combined with paclitaxel in patients with relapsed ovarian cancer (NCT01778803), and in a phase II study in patients with the NSCLC KRAS mutation (NCT01951690).